Table III.3: States Reporting Whether Anticipatory Compounding is Authorized or Allowed in Their State
  Anticipatory compounding authorized or allowed
State Yes, for both sterile and nonsterile compounding Yes, for sterile compounding only Yes, for nonsterile compounding only No No response
Alabama        
Arizona        
Arkansas        
California        
Colorado        
Connecticut        
Delaware        
District of Columbia        
Florida        
Georgia        
Guam        
Hawaii        
Idaho        
Illinois        
Iowa        
Kansas        
Kentucky        
Louisiana        
Maine        
Maryland        
Massachusetts        
Michigan        
Minnesota        
Mississippi        
Missouri        
Montana        
Nebraska        
Nevada        
New Hampshire        
New Jersey        
New Mexico        
New York        
North Carolina        
North Dakota        
Ohio        
Oklahoma        
Oregon        
Pennsylvania        
Rhode Island        
South Carolina        
South Dakota        
Tennessee        
Texas        
Utah        
Vermont        
Virginia        
Washington        
West Virginia        
Wisconsin        
Wyoming        

Source: GAO survey of state pharmacy regulatory bodies, survey question 14. | GAO-17-363SP
Notes: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey.
Anticipatory compounding is the creation of a drug product prior to receipt of an individual patient prescription in anticipation of receiving prescriptions based on historical prescribing patterns.